CD47 and neoplasm: It has also been reported that inhibition of CD47 or SIRPα with antagonistic antibodies enhances the phagocytic activity of TAMs and suppresses tumor growth in preclinical models of glioblastoma [55], melanoma [56], lymphoma [57], and breast [58] and colorectal [59] cancer.